Trial
NCT03192215
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Columbia University
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS); University of Cincinnati; Medical University of South Carolina; Bristol-Myers Squibb; Pfizer; Roche Pharma AG; Weill Medical College of Cornell University; University of Washington
Condition
Stroke
Intervention
Apixaban
Why stopped
The DSMB halted the trial prematurely due to futility without any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-09